AM-Pharma snares $42M venture round for kidney injury trials

Dutch biotech AM-Pharma has scooped up a $42 million venture round designed to push a preclinical alkaline phosphatase program for acute kidney injury through a mid-stage study. And it picked up some cash from two prominent pharma venture groups in the process.

Ysios Capital Partners and Kurma Life Science Partners led the Series D with help from the venture arms of Abbott and Shire. BB Biotech Ventures, Idinvest Partners, Forbion Capital Partners and Inventages Venture Capital also participated.

AM-Pharma's sights are set on a human recombinant form of human alkaline phosphatase, an enzyme that plays a protective role in anti-inflammatory conditions.

"This financing round builds on recent good phase II data with bovine alkaline phosphatase for the treatment of acute kidney injury," says CEO Erik van der Berg. "We are particularly pleased to have our approach validated through the additional support of large pharma."

- here's the AM release

Special Report: Top 5 biotech venture capital deals, H1 2011

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.